IRIS
CASCINU, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.854
AS - Asia 7.586
NA - Nord America 5.442
SA - Sud America 2.268
AF - Africa 181
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 11
AN - Antartide 1
Totale 23.359
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.172
RU - Federazione Russa 4.472
SG - Singapore 2.636
CN - Cina 2.234
BR - Brasile 1.876
HK - Hong Kong 1.042
VN - Vietnam 831
SE - Svezia 782
IT - Italia 751
RO - Romania 550
FR - Francia 381
DE - Germania 270
BD - Bangladesh 269
AR - Argentina 166
GB - Regno Unito 157
IN - India 133
FI - Finlandia 118
CA - Canada 112
MX - Messico 93
ID - Indonesia 78
ZA - Sudafrica 70
AT - Austria 64
EC - Ecuador 63
NL - Olanda 60
PL - Polonia 54
ES - Italia 53
JP - Giappone 49
TR - Turchia 47
IQ - Iraq 46
CO - Colombia 42
IE - Irlanda 31
VE - Venezuela 30
UA - Ucraina 28
CL - Cile 27
MA - Marocco 26
PK - Pakistan 26
PY - Paraguay 26
UZ - Uzbekistan 25
EG - Egitto 22
LT - Lituania 17
SA - Arabia Saudita 17
UY - Uruguay 17
IR - Iran 16
KE - Kenya 16
AE - Emirati Arabi Uniti 15
MY - Malesia 15
PE - Perù 15
NP - Nepal 14
TN - Tunisia 14
AL - Albania 11
AU - Australia 11
DZ - Algeria 11
JM - Giamaica 11
JO - Giordania 11
AZ - Azerbaigian 10
MD - Moldavia 10
EU - Europa 9
HN - Honduras 9
IL - Israele 9
PH - Filippine 9
OM - Oman 8
AO - Angola 7
BY - Bielorussia 7
CR - Costa Rica 6
KZ - Kazakistan 6
LB - Libano 6
NI - Nicaragua 6
PT - Portogallo 6
BB - Barbados 5
BE - Belgio 5
BO - Bolivia 5
SV - El Salvador 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
CH - Svizzera 4
PA - Panama 4
PR - Porto Rico 4
PS - Palestinian Territory 4
TW - Taiwan 4
XK - ???statistics.table.value.countryCode.XK??? 4
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GA - Gabon 3
HR - Croazia 3
KG - Kirghizistan 3
KR - Corea 3
KW - Kuwait 3
SN - Senegal 3
A1 - Anonimo 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BM - Bermuda 2
BS - Bahamas 2
CI - Costa d'Avorio 2
CY - Cipro 2
DK - Danimarca 2
GE - Georgia 2
GR - Grecia 2
GT - Guatemala 2
Totale 23.334
Salva come PNG Salva come JPEG
Città #
Dallas 1.272
Singapore 1.205
Moscow 1.062
Hong Kong 1.033
Ashburn 627
San Jose 567
Shanghai 400
Hefei 368
Ho Chi Minh City 331
Lauterbourg 321
Lawrence 314
Princeton 313
Beijing 302
New York 272
São Paulo 170
Los Angeles 158
Hanoi 153
Milan 111
Helsinki 95
Rome 90
Santa Clara 84
Boardman 73
Nuremberg 69
Munich 67
Orem 63
Rio de Janeiro 59
Warsaw 49
Guangzhou 46
Haiphong 44
Tokyo 41
Belo Horizonte 36
Chicago 36
Denver 36
Brooklyn 35
Chennai 34
Stockholm 33
Brasília 32
Cesano Boscone 32
Montreal 32
Poplar 32
London 31
Vienna 31
Da Nang 30
Dublin 30
Johannesburg 30
Houston 29
Porto Alegre 28
Mexico City 27
The Dalles 26
Toronto 26
Curitiba 24
Frankfurt am Main 24
Guayaquil 24
Naples 24
Tashkent 24
Campinas 23
Manchester 23
Atlanta 22
Council Bluffs 22
Phoenix 22
Amsterdam 21
Ankara 21
Ribeirão Preto 21
Columbus 20
Guarulhos 20
Tianjin 20
Biên Hòa 19
Boston 19
Buffalo 19
Dhaka 19
Quito 19
Thái Bình 19
San Francisco 18
Baghdad 17
Mumbai 17
Buenos Aires 16
Cape Town 16
Montevideo 16
Salvador 16
Hortolândia 15
Shenzhen 15
Washington 15
Hải Dương 14
Nairobi 14
Recife 14
Turku 14
Blumenau 13
Fortaleza 13
Querétaro 13
Brescia 12
Contagem 12
Duque de Caxias 12
Hangzhou 12
Manaus 12
Santo André 12
Seattle 12
Xi'an 12
Asunción 11
Cairo 11
Changsha 11
Totale 11.239
Salva come PNG Salva come JPEG
Nome #
Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines 438
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 430
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 420
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study 349
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience 230
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 136
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 129
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 128
Advanced Digestive Neuroendocrine Tumors Metastatic Pattern Is an Independent Factor Affecting Clinical Outcome 124
DIET AND LIFESTYLE HABITS IN EARLY-ONSET COLORECTAL CANCER. A PILOT CASE-CONTROL STUDY 122
Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe 118
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 117
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 117
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 116
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial 116
Early integration of palliative care in oncology practice: Results of the Italian Association of Medical Oncology (AIOM) survey 113
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments 112
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 112
Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial 111
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 110
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 110
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 110
The evolving role of microsatellite instability in colorectal cancer: A review 110
Addressing the challenges of pancreatic cancer: Future directions for improving outcomes 110
A randomized, double blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel 108
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma 107
Emergency Department Visits among Cancer Patients during SARS-CoV-2 Pandemic 107
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 107
Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC) 106
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study 105
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients 104
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 103
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis 103
Does immunotherapy change the treatment paradigm in metastatic gastric cancer? 103
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX 103
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 102
Role of stereotactic radiosurgery for the treatment of brain metastasis in the era of immunotherapy: A systematic review on current evidences and predicting factors 102
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 101
Metabolism and immune modulation in patients with solid tumors: Systematic review of preclinical and clinical evidence 101
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 100
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors 99
Prediction of early distant recurrence in upfront resectable pancreatic adenocarcinoma: A multidisciplinary, machine learning-based approach 99
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 98
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 98
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 97
Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW 96
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients 96
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 95
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 94
Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma 94
Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma 94
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 92
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 91
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer 91
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor 91
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 90
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients 90
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study 90
Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients 90
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients 89
Cholangiocarcinoma: new perspectives for new horizons 88
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 88
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma? 88
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives 87
5-Fluorouracil pharmacogenomics: still rocking after all these years? 87
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 87
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 86
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 85
To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancer 84
ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib 84
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 83
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 83
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication 82
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients 82
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 81
The role of anti-angiogenics in pre-treated metastatic BRAF-mutant colorectal cancer: A pooled analysis 81
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 80
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 79
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 78
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 77
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 77
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 75
BRAF-mutated colorectal cancer: Clinical and molecular insights 75
Heavily calcified gastrointestinal stromal tumors: Pathophysiology and implications of a rare clinicopathologic entity 75
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 74
Is there a role for chemotherapy after local relapse in high-grade osteosarcoma? 74
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 73
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma 73
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 73
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study 72
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 71
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 71
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 71
Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma: Ready for Prime Time? 71
Il ruolo della radiochirurgia stereotassica nel trattamento delle metastasi cerebrali nell’era dell’immunoterapia: una revisione sistematica sulle evidenze attuali e sui fattori predittivi. 70
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants 70
Evaluation of prognostic factors for survival in transverse colon cancer 70
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 70
Il ruolo della radiochirurgia stereotassica nel trattamento delle metastasi cerebrali nell’era dell’immunoterapia: una revisione sistematica sulle evidenze attuali e sui fattori predittivi 68
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study 68
Totale 10.735
Salva come PNG Salva come JPEG
Categoria #
all - tutte 150.382
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 150.382
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022229 0 1 0 99 7 7 23 43 19 7 6 17
2022/20231.524 736 283 86 8 13 201 41 73 59 6 10 8
2023/2024684 23 38 88 84 43 148 11 61 9 28 46 105
2024/20255.209 624 116 62 58 94 428 1.068 459 831 774 304 391
2025/202615.953 1.098 1.505 1.452 2.200 1.126 540 1.179 1.079 4.012 675 570 517
Totale 23.870